Understand the source comparison
IGF-1 LR3 vs IGF-1 DES: Choosing the Right Analog for Your Research
When researchers move beyond native IGF-1 and begin evaluating synthetic analogs for preclinical work, two peptides come up consistently: IGF-1 LR3 and IGF-1 DES. Both are engineered modifications of the native sequence designed to overcome specific limitation
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- When researchers move beyond native IGF-1 and begin evaluating synthetic analogs for preclinical work, two peptides come up consistently: IGF-1 LR3 and IGF-1 DES. Both are engineered modifications of the native sequence designed to overcome specific limitations of standard IGF-1 — particularly its rapid sequestration by insulin-like growth factor binding proteins (IGFBPs). But they take different structural approaches to solving that problem, and those differences have real consequences for experimental design.
- This article compares IGF-1 LR3 and IGF-1 DES across the dimensions that matter most in a research context: structure, receptor selectivity, IGFBP interactions, half-life, and practical protocol considerations.